Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts

Sponsor
Jinnah Postgraduate Medical Centre (Other)
Overall Status
Completed
CT.gov ID
NCT05023408
Collaborator
(none)
154
1
2
5.9
26

Study Details

Study Description

Brief Summary

The purpose of the study was to determine the efficacy of intralesional bleomycin in comparison to cryotherapy on participants having cutaneous warts.

Condition or Disease Intervention/Treatment Phase
  • Drug: Bleomycin Injection
  • Procedure: Cryotherapy
Phase 2

Detailed Description

This study was conducted in the Department of Dermatology of Jinnah Postgraduate Medical Centre, Karachi from January to June 2021 after receiving approval from the institutional ethical and research committee of hospital.

Sample size was calculated through NCSS software. Total of one fifty four non-admitted patients were assigned two study groups with equal sample size of 77 randomly through lottery method. Those patients aged between 18 to 60 years of either gender with cutaneous warts for

1 week to 48 weeks were included after written informed consent. Patients treated previously for warts by any methodology, with history of vascular disease, immunocompromised, hypertension, cardiovascular disorder, pregnancy, lactation and hypersensitivity to lidocaine were excluded.

All demography, clinical history was recorded by a principal investigator on a predesigned Performa , informed written consent was taken before enrolment.

Group A received intralesional bleomycin 0.1% therapy until the lesion blanched. It was prepared manually by diluting 15 mg powder in 5 ml distilled water and then each ml was further diluted by adding 2ml of 2% lignocaine, double the amount taken from the vial, so that concentration became 1mg/1ml (0.1%). Group B patients were treated with liquid nitrogen with the help of a cotton swab wrapped on a wooden stick and was applied firmly with 01 mm extra healthy skin margin until the lesion blanched.

Follow-up was carried out at 02, 04 and 06 weeks. Both the groups were assessed and compared for efficacy after 6 weeks of therapy. SPSS 23 was used for analyzing data.

Study Design

Study Type:
Interventional
Actual Enrollment :
154 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts
Actual Study Start Date :
Jan 1, 2021
Actual Primary Completion Date :
Jun 30, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intralesional Bleomycin

Intralesional Bleomycin has been given to palmo plantar warts. Generic name: Bleomycin Dose: 1mg/1ml (0.1%) Frequency: every 2 weekly for 6 weeks.

Drug: Bleomycin Injection
Intralesional Bleomycin used for treatment of cutaneous warts.
Other Names:
  • Bleomycin Sulfate
  • Experimental: Cryotherapy

    Cryotherapy has been given to palmo plantar warts. Frequency: every 2 weekly for 6 weeks

    Procedure: Cryotherapy
    Cryotherapy used for comparison of efficacy.

    Outcome Measures

    Primary Outcome Measures

    1. change in morphology of cutaneous warts. [6 weeks]

      There is complete remission of cutaneous warts, assessed clinically

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • • Age18 to 60 years

    • Either gender.

    • Diagnosed cases of cutaneous warts as per operational definition for > 1 week to 48 weeks.

    Exclusion Criteria:
    • • Previously treated for warts by any methodology, assessed by history and clinically.

    • Patients with hypertension, cardiovascular disorder, pregnancy, lactation, vascular diseases, assessed by history, clinically & by positive autoimmune profile.

    • Hypersensitivity to lidocaine.

    • No given informed written consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jinnah Postgraduate Medical Centre Karachi Sindh Pakistan 75510

    Sponsors and Collaborators

    • Jinnah Postgraduate Medical Centre

    Investigators

    • Study Director: Rabia Ghafoor, FCPS, Jinnah Postgraduate Medical Centre

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Javaria Rahmatullah, FCPS II Postgraduate Trainee, Jinnah Postgraduate Medical Centre
    ClinicalTrials.gov Identifier:
    NCT05023408
    Other Study ID Numbers:
    • JinnahPMC
    First Posted:
    Aug 26, 2021
    Last Update Posted:
    Aug 26, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Javaria Rahmatullah, FCPS II Postgraduate Trainee, Jinnah Postgraduate Medical Centre
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 26, 2021